Inhibition of the anti-V3 loop response to a recombinant gp120(SF2) vaccine by preexisting monoclonal antibody

AIDS Research and Human Retroviruses

Volumn 15, Issue 9, 1999, Pages 855-860

  Keller, Margaret A ^a   Arora, Yogesh ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FREUND ADJUVANT; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; VIRUS GLYCOPROTEIN;

ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS INFECTION; VIRUS TRANSMISSION;

AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; VACCINES, SYNTHETIC;

EID: 0032989144     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310764     Document Type: Article

References (12)

1. Jelonek MT, Maskrey JL, Steimer KS, Potts B, Higgins K, and Keller MA: Inhibition of the offspring anti-rgp120 antibody response to a human immunodeficiency virus (HIV) vaccine by maternal immunization in a murine model. J Infect Dis 1995;172: 539-542.
2. Jelonek MT, Maskrey JL, Steimer KS, Potts BJ, Higgins KW, and Keller MA: Maternal monoclonal antibody to the V3 loop alters specificity of the response to a human immunodeficiency virus vaccine. J Infect Dis 1996;174:866-869.
3. Heymann B: The immune complex: Possible ways of regulating the antibody response. Immunol Today 1990;11:310-313.
4. Vakil M, Sauter H, Paige C, and Kearney JF: In vivo suppression of perinatal multispecific B cells results in a distortion of the adult B cell repertoire. Eur J Immunol 1986;16:1159-1165.
5. White-Scharf ME, Potts BJ, Smith LM, Sokolowski KA, Rusche JR, and Silver S: Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization. Virology 1993;192:197-206.
6. Jelonek MT, Maskrey JL, Cummins LM, Arora Y, Steimer KS, White-Scharf M, and Keller MA: HIV hyperimmune globulin or intravenous immune globulin inhibits response to an HIV vaccine. Biotechnol Appl Biochem 1998;27:89-95.
7. Seiler P, Brundler A, Zimmermann C, Weibel D, Bruns M, Hengartner H, and Zinkernagel RM: Induction of protective cytotoxic T cell response in the presence of high titers of virus-neutralizing antibodies: Implications for passive and active immunization. J Exp Med 1998;187:649-654.
8. Earl PL, Broder CC, Long D, Lee SA, Peterson J, Chakrabarti S, Doms RW, and Moss B: Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 1994;68:3015-3026.
9. Kohler H, Müller S, and Nara PL: Deceptive imprinting in the immune response against HIV-1. Immunol Today 1994;10:475-478.
10. O'Toole C, Müller S, Nara P, and Kohler H: Immunologic mechanism for human immunodeficiency virus type 1 gp120 vaccine failure. J Infect Dis 1996;173:512-513.
11. Garrity RR, Rimmelzwaan G, Minassian A, Tsai W-P, Lin G, De Jong J-J, Goudsmit J, and Nara PL: Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol 1997;159:279-289.
12. Kmieciak D, Wasik TJ, Teppler H, Pientka J, Hsu SH, Takahashi H, Okumura K, Kaneko Y, and Kozbor D: The effect of deletion of the V3 loop of gp120 on cytotoxic T cell responses and HIV gp120-mediated pathogenesis. J Immunol 1998;160:5676-5683.